Results 171 to 180 of about 4,513 (197)

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

New England Journal of Medicine, 2020
Manisha Balwani, Eliane Sardh, Paolo Ventura   +2 more
exaly  

EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks

Hepatology, 2020
Paolo Ventura, Manisha Balwani, David C Rees   +2 more
exaly  

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

Liver International, 2022
Paolo Ventura, Herbert L Bonkovsky, Manisha Balwani   +2 more
exaly  

Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals

Journal of Internal Medicine, 2022
Mattias Lissing, Daphne Vassiliou, Ylva Floderus   +2 more
exaly  

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

Nature Medicine, 2018
Pedro Berraondo, Daniel Jericó, Lin T Guey   +2 more
exaly  

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

Clinical Pharmacology and Therapeutics, 2020
Sagar Agarwal
exaly  

Givosiran: A Review in Acute Hepatic Porphyria

Drugs, 2021
exaly  

Porphyria

New England Journal of Medicine, 2017
D Montgomery Bissell, Karl E Anderson, Herbert L Bonkovsky   +2 more
exaly  

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

New England Journal of Medicine, 2019
Eliane Sardh, Pauline Harper, Manisha Balwani   +2 more
exaly  

Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α

Cell, 2005
Christoph Handschin, Yan Lu, Pei-Hsuan Wu   +2 more
exaly